On this page
This entry or formulation may be investigational and may not correspond to an FDA-approved product; safety and efficacy may not have been established. Kairo lists it for identification and record-keeping only.
Overview
Product & regulatory status
The research summarized here does not establish clinical senolytic treatment in humans.
FOXO4 and p53
The proposed mechanism interrupts an interaction between FOXO4 and p53, allowing programmed cell death in susceptible senescent cells. This is a targeted experimental mechanism, not a measured outcome available from Kairo logs. [1]
What the evidence shows
Foundational mouse study
A 2017 study disrupted FOXO4-p53 signaling and reported improvements in selected tissue and physical outcomes in chemotherapy-stressed and aging mice. These outcomes cannot be interpreted as proven human rejuvenation. [1]
Hormonal research is also preclinical
A later study examined senescent Leydig cells and aging mice, reporting effects on the testicular environment and testosterone-related measures. It was not a treatment trial in men with low testosterone. [2]
What remains unknown
Human selectivity, durable benefit, cancer-related consequences, and safe treatment exposure remain unanswered by these experiments.
Safety
Cell clearance needs clinical validation
A compound designed to trigger cell death requires careful evaluation of which cells it reaches and affects. Mouse tolerability does not establish the safety of repeated administration in people. [1]
Engineered research peptide
The mouse study concerns the engineered FOXO4-DRI peptide, not simply the natural FOXO4 protein. Its cell-targeting design and experimental preparation do not establish a clinically validated consumer formulation. [1]
Understanding product quality
Compounded drugs are not FDA-approved finished products. Poor preparation can cause contamination or incorrect strength. A catalog entry or a research paper is not a quality assessment of your product. [3]
When to seek urgent help
Severe allergic symptoms such as trouble breathing, throat or tongue swelling, or fainting need immediate help. Call 911 or your local emergency number. This is general emergency information, not a complete list of risks for this compound. [4]
A starting point for discussion
This is not a complete list of adverse effects or interactions. Your health history, other medicines, and the exact formulation matter. Missing safety data is not evidence of safety.
Common questions
Does it remove all harmful aging cells?
The studies examined particular models and pathways. They do not validate a whole-body cleanse or guarantee that every senescent cell is harmful.
Questions for your clinician
Does the evidence match my condition and this exact product? What risks or interactions matter for me? How would we assess whether it is helping?
Sources
- FOXO4-targeted senescent cell removal in mice2017 · Original research · PubMed
- FOXO4-DRI and aging Leydig cells2020 · Original research · PubMed
- Compounding and the FDA: Questions and AnswersFDA · product quality and regulation
- AnaphylaxisMedlinePlus · recognizing an emergency
Educational information, not a recommendation to use a compound. Kairo does not give dosing advice. Review decisions with a licensed healthcare professional.